APIs & injectables
From active pharmaceutical ingredients (APIs) through formulation and injectable delivery considerations—designed around control, quality, and scale.
API strategy
Portfolio selection, sourcing pathways, and operational planning aligned to repeatable, scalable output.
Injectable pathways
Injectable delivery intent: stability, handling, and pathway-to-market thinking (implementation depends on partners).
Quality discipline
Quality-by-design framing and measurable controls to support scale, trust, and repeatability.
API strategy
Portfolio selection, sourcing pathways, and operational planning aligned to repeatable, scalable output.
Portfolio selection
API portfolio selection is a strategic decision with long-term consequences for product quality, supply security, and regulatory compliance. Medyra Health's portfolio selection frameworks balance therapeutic need, synthesis complexity, IP position, starting material availability, and long-term supply security—ensuring that every API selected for development has a credible, sustainable, and quality-assured supply pathway from day one of development planning.
Supply planning
Sourcing pathways are designed with multi-source capability, risk stratification by supplier tier, and contingency sourcing plans that protect against single-source failure, regulatory non-compliance, or geopolitical supply disruption. Medyra Health builds supply planning into the development roadmap at the earliest feasibility stage—not as a late-stage commercial afterthought.
Controls
Operational planning aligned to repeatable, scalable output requires robust process controls—including in-process controls, release testing specifications, and ongoing stability programme management. Medyra Health's control frameworks are aligned to ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients) and designed to scale from development to commercial manufacture without major redesign.
Process development
Synthesis route scouting, process optimisation, and scale-up pathway planning from laboratory through pilot to commercial manufacturing intent.
Analytical development
Analytical method development and validation aligned to ICH guidelines, supporting regulatory submissions and ongoing quality control requirements.
Supplier qualification
Rigorous supplier assessment, audit, and ongoing qualification frameworks that ensure API supply quality is maintained consistently across the supply chain.
images/api-strategy.jpg
Injectable pathways
Injectable delivery intent: stability, handling, and pathway-to-market thinking (implementation depends on partners).
images/injectables-delivery.jpg
Injectables
Injectable delivery is one of the most technically demanding—and commercially critical—pharmaceutical formats. Medyra Health's injectable pathway expertise spans subcutaneous, intramuscular, intravenous, and intrathecal routes, with deep understanding of formulation requirements, primary container compatibility, device integration, and the regulatory expectations that govern each delivery format across major jurisdictions.
Stability mindset
Stability is not a technical checkbox—it is a fundamental determinant of product viability, shelf life, and patient safety. Medyra Health embeds a stability mindset into every injectable programme from the earliest formulation concept, designing stability-indicating assays, accelerated and real-time stability protocols, and storage condition specifications aligned to ICH Q1A–Q1F guidelines—ensuring that stability data is generated systematically and supports both regulatory submission and commercial supply planning.
Delivery planning
Pathway-to-market thinking—understanding the full arc of regulatory, clinical, and commercial steps required to bring an injectable product to patients—is built into every Medyra Health injectable programme. Implementation depends on partners: we design the pathway and provide the strategic and technical framework; execution is delivered through qualified CMO partners and clinical research organisations with the specialist facility infrastructure required for GMP injectable manufacture.
Quality discipline
Quality-by-design framing and measurable controls to support scale, trust, and repeatability.
QbD mindset
Quality-by-design (QbD) is not a regulatory formality—it is a fundamental approach to pharmaceutical development that embeds quality into the product and process design, rather than attempting to test quality in at the end. Medyra Health applies QbD principles from the earliest stages of development: defining critical quality attributes (CQAs), identifying critical process parameters (CPPs), and designing manufacturing controls that ensure CQAs are consistently met at every scale.
Traceability
Full traceability—from raw material sourcing through manufacturing, quality control, batch release, and distribution to the patient—is a non-negotiable requirement of GMP pharmaceutical manufacture. Medyra Health's traceability frameworks are designed to meet the expectations of MHRA, EMA, and FDA inspectors, and to support the serialisation and track-and-trace requirements mandated under EU FMD and US DSCSA legislation.
Repeatability
Measurable controls to support scale, trust, and repeatability require a robust process validation framework, clear specifications, and a continuous improvement culture that identifies and eliminates sources of variability before they become patient safety issues. Medyra Health's repeatability frameworks incorporate statistical process control, CAPA management, and quality trending tools that support sustained, measurable manufacturing performance throughout the product lifecycle.
images/quality-facility.jpg
Portfolio selection
Choosing the right APIs to develop and supply
API portfolio selection is a strategic decision that shapes the entire downstream development and supply chain architecture. The right API — with appropriate IP position, synthesis route simplicity, starting material availability, and regulatory track record — dramatically reduces development risk and time to market. Medyra Health's portfolio selection frameworks assess all relevant dimensions before committing to API development investment.
IP landscape analysis
Freedom-to-operate analysis, patent expiry mapping, and alternative synthesis route identification — ensuring that API development investment is protected and that the regulatory exclusivity position of each API is fully understood.
Synthesis route assessment
Comparative synthesis route evaluation across yield, step count, solvent and reagent availability, safety profile, and scalability — selecting routes that are both technically optimal and economically viable at commercial scale.
Regulatory track record
DMF availability assessment, regulatory filing history review, and comparator data gap analysis — establishing the regulatory baseline for each API and identifying the additional work required to support a complete NDA or MAA submission.
Supply planning
Securing the supply chain from raw material to release
Supply planning for pharmaceutical APIs requires a systematic approach to identifying, qualifying, and managing the network of raw material suppliers, contract manufacturers, and logistics partners that collectively deliver consistent, GMP-compliant API to formulation facilities on time and to specification. Medyra Health builds supply planning into the development roadmap from the earliest feasibility stage — treating supply security as a development deliverable, not a commercial afterthought.
Supplier qualification
ICH Q7-aligned supplier audit frameworks, qualification protocols, and ongoing performance monitoring systems — ensuring that every API supplier in Medyra Health's network meets GMP requirements and performs consistently against agreed quality and delivery KPIs.
Contingency sourcing
Secondary and tertiary source qualification, strategic inventory management, and supply disruption response protocols — protecting clinical trial and commercial supply against the supplier failures, regulatory actions, and force majeure events that periodically disrupt pharmaceutical supply chains.
Controls
Measurable quality at every step of the manufacturing process
Manufacturing controls for pharmaceutical APIs are the technical and procedural safeguards that ensure every batch meets its predefined quality specifications — consistently, traceably, and to a standard that satisfies the most rigorous regulatory expectations. Medyra Health's control strategy design is based on quality-by-design (QbD) principles — identifying critical quality attributes (CQAs) and critical process parameters (CPPs) systematically, and designing controls that protect CQAs at every stage of the manufacturing process.
In-process controls
Real-time process monitoring, in-line and at-line analytical measurement, and process analytical technology (PAT) integration — enabling active process management rather than end-product testing as the primary quality assurance mechanism.
Release testing
Specification design, analytical method development and validation, and release testing protocol design — aligned to ICH Q6A/Q6B and the specific regulatory requirements of target submission jurisdictions.
Stability programme
ICH Q1A–Q1F compliant stability programme design, including accelerated, intermediate, and long-term conditions, primary container compatibility, and photostability testing — generating the data package required for regulatory submission and shelf-life determination.
Injectables
From formulation concept to patient-ready product
Injectable pharmaceutical products are among the most technically demanding to develop and manufacture — requiring sterile processing, particle-free formulation, primary container compatibility, and device integration, all under GMP conditions that meet the highest regulatory standards. Medyra Health's injectable development capability covers the full development arc from initial formulation concept and excipient selection through clinical batch manufacture, process validation, and commercial-scale technology transfer to qualified CMO partners.
Formulation development
Injectable formulation design for small molecule, peptide, and biologic APIs — including buffer system selection, tonicity adjustment, stabiliser evaluation, and preservative effectiveness testing for multi-dose presentations.
Sterile processing
Terminal sterilisation versus aseptic processing route selection, sterilisation validation strategy, and aseptic process simulation (media fill) programme design — aligned to Annex 1 and FDA guidance for sterile product manufacture.
Device integration
Primary container and delivery device selection, container closure integrity testing, leachable and extractable study design, and human factors engineering for patient-administered injectable devices.
Stability mindset
Building product durability into every formulation decision
Stability — the ability of a pharmaceutical product to maintain its chemical, physical, microbiological, and toxicological properties within specified limits throughout its intended shelf life — is not just a regulatory requirement. It is a fundamental determinant of patient safety, commercial viability, and supply chain practicality. A product with inadequate stability cannot be stored, distributed, or administered safely; it cannot be approved for marketing; and it cannot be supplied reliably to patients who need it. Medyra Health embeds stability thinking into every formulation decision from the earliest concept stage.
Forced degradation studies
Systematic stress testing across hydrolytic, oxidative, photolytic, thermal, and pH conditions — identifying the key degradation pathways and degradation products of each API to guide stability-indicating method development and formulation optimisation.
Cold chain strategy
Storage condition selection, cold chain qualification, and distribution model design — balancing product stability requirements against the logistical and commercial constraints of the target healthcare market and distribution network.
Delivery planning
The full pathway from development to patient
Delivery planning is the process of defining and executing the complete pathway from development concept to patient access — spanning regulatory strategy, manufacturing scale-up, market access, distribution network design, and healthcare professional engagement. Medyra Health's delivery planning frameworks are designed to ensure that clinical success translates into patient access efficiently and at the scale the market requires.
Regulatory pathway
Regulatory submission strategy design across standard, accelerated, and adaptive approval pathways — identifying the fastest credible route to market in each target jurisdiction while maintaining the highest standards of regulatory integrity.
Market access
Reimbursement strategy, HTA submission design, managed access programme frameworks, and patient access scheme negotiation — translating regulatory approval into funded patient access in target healthcare systems.
Distribution design
Distribution network architecture, 3PL partner selection, serialisation and track-and-trace implementation, and cold chain logistics management — ensuring product integrity from manufacturing site to point of dispensing or administration.
QbD mindset
Quality built in, not tested in
Quality by Design (QbD) is the ICH Q8/Q9/Q10/Q11 framework for pharmaceutical development that embeds quality into the product and process design rather than relying on end-product testing to confirm it. QbD starts with a clearly defined quality target product profile (QTPP), identifies critical quality attributes (CQAs) that determine whether the QTPP is met, and systematically maps the process parameters and material attributes (CPPs and CMAs) that most influence each CQA — designing control strategies that consistently deliver the required product quality.
QTPP & CQA definition
Quality target product profile development and critical quality attribute identification — establishing the complete quality specification that the development programme must deliver and demonstrating how each attribute is controlled.
Design space development
Multivariate design of experiments (DoE), response surface methodology, and design space definition — establishing the proven acceptable ranges for process parameters that consistently deliver the required product quality.
Control strategy design
Integrated control strategy development — defining the combination of process controls, in-process tests, and release specifications that collectively provide the highest assurance of consistent product quality at commercial scale.
Traceability
Complete visibility from raw material to patient
Full pharmaceutical traceability — the ability to trace any unit of product through every step of its manufacturing, testing, storage, and distribution history — is both a regulatory requirement and a patient safety imperative. In an era of complex global supply chains, increasing serialisation requirements, and growing regulatory scrutiny of supply chain integrity, traceability is also a commercial differentiator that builds partner and customer confidence. Medyra Health's traceability frameworks are designed to meet current and anticipated future regulatory requirements across all major markets.
Batch genealogy
Complete batch manufacturing record design, electronic batch record implementation, and raw material genealogy tracking — creating an unbroken chain of custody and quality documentation for every batch from raw material receipt to finished product release.
Serialisation
EU FMD and US DSCSA-compliant serialisation implementation — unique identifier assignment, tamper-evident seal application, aggregation, and repository connectivity — meeting current and anticipated future track-and-trace requirements in major markets.
Audit trail integrity
Electronic audit trail configuration, 21 CFR Part 11 compliance assessment, and data integrity programme management — ensuring that all electronic records are complete, accurate, consistent, and attributable to the individuals who created them.
Repeatability
The same quality, every batch, every time
Manufacturing repeatability — the consistent production of pharmaceutical product that meets all quality specifications, batch after batch, at commercial scale — is the ultimate goal of pharmaceutical process development. It is also the attribute most difficult to achieve and maintain as manufacturing operations scale, mature, and encounter the inevitable raw material variability, equipment ageing, and operator turnover that characterise commercial pharmaceutical production. Medyra Health's repeatability frameworks build statistical process control, continuous process verification, and quality culture into manufacturing operations from the earliest clinical batch stages.
Process validation
Stage 1–3 process validation planning and execution — from process design through process qualification to continued process verification — aligned to FDA process validation guidance and EMA process validation guideline requirements.
Statistical process control
Control chart design, process capability analysis (Cpk, Ppk), and special cause variation detection frameworks — providing real-time manufacturing performance monitoring and early warning of process drift before specification exceedances occur.
CAPA management
Root cause analysis methodology, corrective and preventive action design, effectiveness verification, and CAPA closure criteria — ensuring that deviations and non-conformances are resolved permanently rather than repeatedly managed as recurring issues.